304873-62-9

Basic information

• Product Name: 2-Boc-amino-4-hydroxymethylpyridine
• Synonyms: 2-Boc-amino-4-hydroxymethylpyridine;[4-(Hydroxymethyl)-2-pyridinyl]carbamic acid 1,1-dimethylethyl ester;2-(Boc-amino)-4-pyridinemethanol;(4-Hydroxymethyl-pyridin-2-yl)-carbamic acid tert-butyl ester
• CAS NO: 304873-62-9
• Molecular Formula: C₁₁H₁₆N₂O₃
• Molecular Weight: 224.26
• Product Categories: pharmacetical
• Mol File: 304873-62-9.mol
• Article Data: 20

Chemical Properties

• Melting Point: 137-138 °C
• Boiling Point: 333.4°Cat760mmHg
• Flash Point: 155.4°C
• Appearance: /
• Density: 1.209g/cm³
• Vapor Pressure: 5.45E-05mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: 2-8°C
• PKA: 12.40±0.70(Predicted)
• CAS DataBase Reference: 2-Boc-amino-4-hydroxymethylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Boc-amino-4-hydroxymethylpyridine(304873-62-9)
• EPA Substance Registry System: 2-Boc-amino-4-hydroxymethylpyridine(304873-62-9)

Safety Data

• Hazardous Substances Data: 304873-62-9(Hazardous Substances Data)

Usage

General Description

2-Boc-amino-4-hydroxymethylpyridine is a chemical compound commonly used in organic synthesis and pharmaceutical research. It is a derivative of pyridine and contains both an amino and a hydroxyl group. The Boc (tert-butoxycarbonyl) protecting group is often used to protect the amine functionality during chemical reactions, allowing for selective manipulation of other functional groups in the molecule. The hydroxymethyl group also provides opportunities for further derivatization, making this compound useful for the synthesis of various pharmaceuticals and biologically active molecules. Additionally, the pyridine ring imparts aromaticity and contributes to the molecule's overall reactivity and potential interactions in biological systems. Overall, 2-Boc-amino-4-hydroxymethylpyridine is a versatile chemical building block with potential applications in drug discovery and development.

InChI:InChI=1/C11H16N2O3/c1-11(2,3)16-10(15)13-9-6-8(7-14)4-5-12-9/h4-6,14H,7H2,1-3H3,(H,12,13,15)

Upstream product

• 639091-75-1 methyl 2-[(tert-butoxycarbonyl)amino]isonicotinate 
• 305329-03-7 2-[N,N-bis(tert-butoxycarbonyl)amino]isonicotinic acid ethyl ester 
• 90101-20-5 tert-Butyl N-(4-methyl-pyridin-2-yl)carbamate 
• 6313-54-8 2-chloroisonicotinic acid, 
• 13362-28-2 2-aminoisonicotinic acid 
• 304873-65-2 2-[N,N-mono-(tert-butoxycarbonyl)amino]-pyridyl-4-aldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 105250-17-7 2-amino-4-hydroxymethylpyridine 
• 6937-03-7 methyl 2-aminoisonicotinate 
• 695-34-1 2-Amino-4-methylpyridine 

Downstream Products

• 190189-98-1 (4-bromomethylpyridin-2-yl)carbamic acid tert-butyl ester 
• 105250-17-7 2-amino-4-hydroxymethylpyridine 
• 304873-65-2 2-[N,N-mono-(tert-butoxycarbonyl)amino]-pyridyl-4-aldehyde 
• 639091-78-4 tert-butyl [4-(aminomethyl)pyridin-2-yl]carbamate 
• 639091-77-3 tert-butyl {4-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]pyridin-2-yl}carbamate 
• 1446252-28-3 (Z)-4-(4-fluorostyryl)-pyridin-2-amine 
• 1446252-29-4 (Z)-tert-butyl 4-(4-fluorostyryl)pyridin-2-yl(isopropyl)carbamate 
• 1446252-30-7 (Z)-4-(4-fluorostyryl)-N-isopropylpyridin-2-amine 
• 1446252-33-0 (E)-ethyl 3-(2-(tert-butoxycarbonylamino)pyridin-4-yl)-2-phenyl-acrylate 
• 1446252-34-1 (E)-ethyl 3-(2-(tert-butoxycarbonylamino)pyridin-4-yl)-2-(4-fluorophenyl) acrylate 
• 1446252-36-3 (E)-ethyl 3-(2-aminopyridin-4-yl)-2-phenyl acrylate 
• 1446252-37-4 (E)-ethyl 3-(2-aminopyridine-4-yl)-2-(4-fluorophenyl)acrylate 

Relevant articles and documents

AMINOPYRIDINE COMPOUNDS AND METHODS FOR THE PREPARATION AND USE THEREOF

The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula III, as described herein, and pharmaceutically acceptable salts thereof.

COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER

The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.